AM-2-19 explained

AM-2-19 is an experimental antifungal drug based on amphotericin B (AmB) that is engineered to be less toxic to the kidneys.^{[1] [2] [3]} Amphotericin B, a polyene group of molecule targets fungal ergosterol as well as human cholesterol, results in kidney damage. While AM-2-19 or SF001, initially developed by Sfunga Therapeutics, and now being developed by Elion Therapeutics, not only selective to fungal ergosterol but also draws out fungal ergosterol more effectively. The investigational new drug (IND) application was filed in May 2023. SF001 received Qualified Infectious Disease Product (QIDP) for invasive aspergillosis and Fast Track designations from the FDA in 2023. It is now under phase I trial. An oral formulation is currently in the feasibility phase.

Notes and References

1. News: New antifungal kills without toxic side effects. . 19 November 2023.
2. Maji . Arun . Soutar . Corinne P. . Zhang . Jiabao . Lewandowska . Agnieszka . Uno . Brice E. . Yan . Su . Shelke . Yogesh . Murhade . Ganesh . Nimerovsky . Evgeny . Borcik . Collin G. . Arango . Andres S. . Lange . Justin D. . Marin-Toledo . Jonnathan P. . Lyu . Yinghuan . Bailey . Keith L. . Roady . Patrick J. . Holler . Jordan T. . Khandelwal . Anuj . SantaMaria . Anna M. . Sanchez . Hiram . Juvvadi . Praveen R. . Johns . Gina . Hageman . Michael J. . Krise . Joanna . Gebremariam . Teclegiorgis . Youssef . Eman G. . Bartizal . Ken . Marr . Kieren A. . Steinbach . William J. . Ibrahim . Ashraf S. . Patterson . Thomas F. . Wiederhold . Nathan P. . Andes . David R. . Pogorelov . Taras V. . Schwieters . Charles D. . Fan . Timothy M. . Rienstra . Chad M. . Burke . Martin D. . Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal . Nature . 8 November 2023 . 623 . 7989 . 1079–1085 . 10.1038/s41586-023-06710-4 . 37938782 . 2023Natur.623.1079M . 265048011 . en . 1476-4687. 10883201 .
3. News: Antifungal analog offers reduced toxicity . 19 November 2023 . Chemical & Engineering News . en.